We are live on ! Find out more
AAA

Affinity Asset Advisors Portfolio holdings

AUM $2.21B
1-Year Est. Return 431.26%
This Fund
S&P 500
This Quarter Est. Return
+75.99%
1 Year Est. Return
+431.26%
3 Year Est. Return
+1,487.3%
5 Year Est. Return
+3,318.95%
10 Year Est. Return
–
AUM
$1.76B
AUM Growth
+$607M
Cap. Flow
-$52.4M
Cap. Flow %
-2.99%
Top 10 Hldgs %
43.13%
Holding
124
New
28
Increased
25
Reduced
20
Closed
29

Top Buys

Rank Stock Value
1
PRAX icon
Praxis Precision Medicines
PRAX
+$34.5M
2
CYTK icon
Cytokinetics
CYTK
+$28M
3
VTYX
Ventyx Biosciences
VTYX
+$19.1M
4
ROIV icon
Roivant Sciences
ROIV
+$17.8M
5
FBRX
Forte Biosciences
FBRX
+$17.3M

Top Sells

Rank Stock Value
1
VRNA
Verona Pharma
VRNA
+$66.7M
2
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$56.3M
3
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$42.8M
4
MRUS
Merus
MRUS
+$26.9M
5
SLNO
Soleno Therapeutics
SLNO
+$13.5M

Sector Composition

Rank Sector Weight
1 Healthcare 76.68%
2 Miscellaneous 23.28%
3 Financials 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OBIO icon
76
Orchestra BioMed
OBIO
$305M
$2.38M 0.14%
572,804
-154,468
-21% -$623K
EPRX
77
Eupraxia Pharmaceuticals
EPRX
$555M
$2.27M 0.13%
300,000
– –
GERN icon
78
Geron
GERN
$1.01B
$1.98M 0.11%
1,500,000
– –
RARE icon
79
Ultragenyx Pharmaceutical
RARE
$1.51B
$1.73M 0.1%
+75,000
New +$2.47M
LENZ
80
PUT
LENZ Therapeutics
LENZ
$187M
$1.6M 0.09%
+100,000
New +$2.91M
KZR
81
DELISTED
Kezar Life Sciences
KZR
$1.44M 0.08%
+229,076
New +$1.34M
CMPS
82
Compass Pathways
CMPS
$1.84B
$1.38M 0.08%
200,000
– –
QURE icon
83
uniQure
QURE
$3.09B
$1.2M 0.07%
50,000
-250,000
-83% -$9.65M
CATX icon
84
Perspective Therapeutics
CATX
$357M
$825K 0.05%
300,000
– –
MGNX icon
85
MacroGenics
MGNX
$280M
$780K 0.04%
+484,308
New +$761K
PCSC
86
DELISTED
Perceptive Capital Solutions
PCSC
$652K 0.04%
50,000
-300,000
-86% -$3.5M
FBRX
87
CALL
DELISTED
Forte Biosciences
FBRX
$611K 0.03%
+22,400
New +$393K
XFOR icon
88
X4 Pharmaceuticals
XFOR
$401M
$580K 0.03%
+145,000
New +$527K
QTTB icon
89
Q32 Bio
QTTB
$357M
$92.2K 0.01%
27,777
– –
ADGM
90
Adagio Medical Holdings
ADGM
$12.5M
$83.2K ﹤0.01%
80,000
– –
RCKTW
91
DELISTED
Rocket Pharmaceuticals Warrant
RCKTW
$1.82K ﹤0.01%
75,000
– –
AKBA icon
92
Akebia Therapeutics
AKBA
$270M
– –
-2,450,000
Closed -$6.69M
ATXS
93
DELISTED
Astria Therapeutics
ATXS
– –
-300,000
Closed -$2.18M
AUTL
94
Autolus Therapeutics
AUTL
$596M
– –
-1,750,000
Closed -$2.85M
CNTX icon
95
Context Therapeutics
CNTX
$33.2M
– –
-402,653
Closed -$390K
ELVN icon
96
Enliven Therapeutics
ELVN
$4.35B
– –
-400,000
Closed -$8.19M
EXEL icon
97
CALL
Exelixis
EXEL
$14.6B
– –
-150,000
Closed -$6.2M
EXEL icon
98
PUT
Exelixis
EXEL
$14.6B
– –
-350,000
Closed -$14.5M
CBIO
99
Crescent Biopharma
CBIO
$776M
– –
-17,998
Closed -$214K
INSM icon
100
CALL
Insmed
INSM
$27.6B
– –
-205,000
Closed -$29.5M
1 2 3
4
5

Similar funds

BCP
BSN Capital Partners London, United Kingdom $2.21B AUM 22.85% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.21B AUM 28.12% 1-Year Est. Return
IHL
Investment House LLC Redondo Beach, California $2.21B AUM 39.6% 1-Year Est. Return
1SB
1ST Source Bank South Bend, Indiana $2.21B AUM 28.75% 1-Year Est. Return
CCA
Checchi Capital Advisers Beverly Hills, California $2.22B AUM 23.18% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2.22B AUM 32.92% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
LI
Leeward Investments Boston, Massachusetts $2.2B AUM 46.08% 1-Year Est. Return

Affinity Asset Advisors's Q4 2025 Portfolio in Review

As of Q4 2025, Affinity Asset Advisors held 124 positions worth $1.76B, up 53% from $1.15B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Affinity Asset Advisors's Q4 2025 filing shows 28 new, 25 increased, 20 reduced and 29 closed positions. Its largest new stake was Praxis Precision Medicines: 185,000 shares worth $54.5M. The largest sale was Verona Pharma, an estimated $66.7M.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, down from 85% a quarter earlier, followed by Miscellaneous and Financials.

  • Affinity Asset Advisors's largest Q4 2025 buy was Praxis Precision Medicines: 185,000 shares worth $54.5M.
  • Affinity Asset Advisors added most to Cytokinetics in Q4 2025, an estimated $28M increase.
  • Affinity Asset Advisors's biggest Q4 2025 reduction was Madrigal Pharmaceuticals, cutting an estimated $42.8M.
  • Affinity Asset Advisors fully exited Verona Pharma in Q4 2025, selling an estimated $66.7M.
  • Affinity Asset Advisors's ten largest holdings make up 43% of its $1.76B portfolio in Q4 2025.
  • Affinity Asset Advisors opened 28 new positions and closed 29 in Q4 2025.
  • Affinity Asset Advisors's portfolio value rose 53% quarter-over-quarter to $1.76B.

Based on Affinity Asset Advisors's 13F filing for Q4 2025, filed 13 Feb 2026.